368 related articles for article (PubMed ID: 28412198)
1. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
Sultan Alvi S; Ansari IA; Khan I; Iqbal J; Khan MS
Free Radic Biol Med; 2017 Jul; 108():394-403. PubMed ID: 28412198
[TBL] [Abstract][Full Text] [Related]
2. Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity.
Alvi SS; Ansari IA; Ahmad MK; Iqbal J; Khan MS
Biomed Pharmacother; 2017 Dec; 96():1082-1093. PubMed ID: 29174038
[TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
4. Keep recycling going: New approaches to reduce LDL-C.
Klein-Szanto AJP; Bassi DE
Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636
[TBL] [Abstract][Full Text] [Related]
5. Insights into pharmacological mechanisms of polydatin in targeting risk factors-mediated atherosclerosis.
Ahmad P; Alvi SS; Iqbal D; Khan MS
Life Sci; 2020 Aug; 254():117756. PubMed ID: 32389832
[TBL] [Abstract][Full Text] [Related]
6. Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality.
Wang G; Liu Z; Li M; Li Y; Alvi SS; Ansari IA; Khan MS
Biomed Res Int; 2019; 2019():7284767. PubMed ID: 31281844
[TBL] [Abstract][Full Text] [Related]
7. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis.
Strålberg T; Nordenskjöld A; Cao Y; Kublickiene K; Nilsson E
Eur J Clin Invest; 2019 Jul; 49(7):e13113. PubMed ID: 30921469
[TBL] [Abstract][Full Text] [Related]
10. Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.
Waiz M; Alvi SS; Khan MS
EXCLI J; 2022; 21():47-76. PubMed ID: 35221836
[TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
12. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.
Wierzbicki AS; Hardman TC; Viljoen A
Expert Opin Investig Drugs; 2012 May; 21(5):667-76. PubMed ID: 22493980
[TBL] [Abstract][Full Text] [Related]
14. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
15. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
17. Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE
Gu L; Gong Y; Zhao C; Wang Y; Tian Q; Lei G; Liang Y; Zhao W; Tan S
Molecules; 2019 Nov; 24(22):. PubMed ID: 31731717
[TBL] [Abstract][Full Text] [Related]
18. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
[TBL] [Abstract][Full Text] [Related]
19. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
